for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Krystal Biotech Inc

KRYS.O

Latest Trade

--

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

--

 - 

--

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
--
Open
--
Volume
--
3M AVG Volume
3.75
Today's High
--
Today's Low
--
52 Week High
--
52 Week Low
--
Shares Out (MIL)
17.31
Market Cap (MIL)
1,084.20
Forward P/E
-51.22
Dividend (Yield %)
--

Latest Developments

More

Krystal Biotech Reports Third Quarter 2019 Financial And Operating Results

Krystal Biotech Announces Final Update From Phase 1/2 Clinical Trial Of Kb103

Krystal Biotech Receives Positive EMA Opinion On Orphan Designation For KB105

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Krystal Biotech Inc

Krystal Biotech, Inc. is a gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases. The Company’s products include KB103 and KB104.The Company's KB103 is in preclinical development to treat dystrophic epidermolysis bullosa, or DEB, a rare and severe genetic disease. The Company's KB104 is to treat Netherton Syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation, itchiness and dehydration.

Industry

Biotechnology & Drugs

Contact Info

2100 Wharton St Ste 701

+1.412.5865830

https://www.krystalbio.com/

Key Stats

1.71 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-1.480

2018

-0.970

2019(E)

-1.223
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
5.22
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-13.26
Return on Equity (TTM)
-12.98

Latest News

Latest News

BRIEF-Krystal Biotech reports qtrly loss per share $1.26

* Krystal Biotech reports that KB103 received clearance from RAC review and announces third quarter 2017 financial results

BRIEF-Krystal Biotech says KB103 granted orphan drug designation by FDA

* Krystal Biotech’s KB103 granted orphan drug designation by the FDA to treat patients with dystrophic epidermolysis bullosa

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up